NYSE:RCUSBiotechs
What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders
In the second quarter of 2026, Arcus Biosciences reported revenue of US$41 million versus US$160 million a year earlier, with a net loss of US$91 million and basic and diluted loss per share of US$0.72.
For the first half of 2026, revenue fell to US$58 million from US$188 million while net loss widened to US$219 million, even as the company forecast full-year GAAP revenue of US$65 million to US$75 million.
With Arcus now projecting full-year 2026 revenue of just US$65 million to US$75...